生命徵象
診斷
主觀描述
客觀描述
評估與計畫
處方
帶入
診斷
帶入到

序號    診斷碼    診斷名稱
1    C34.90    Malignant neoplasm of unspecified part of unspecified bronchus or lung
2    J44.9    Chronic obstructive pulmonary disease, unspecified
主觀描述
帶入到
S
O
A/P

# Care plan for patient with lung cancer #

Mr. Yang, a 70 y/o man with the diagnosis of squamous cell carcinoma of the lung in 2021, post vinorelbine/cisplatin in combination with radiation therapy, recurrent disease in 2023, post vinorelbine, progression of disease in 2025/03, and been suggested to do gemcitabine w/ or w/o cisplatin. 

progressive DOE with stridor(?) for 1 week, no productive cough, no fever
** improving after Salbutamol INH (no regular used)

admitted DOE
客觀描述
帶入到
S
O
A/P

KPS: 80% (ECOG=1), regular pulse
No distress and oriented fully
Intact oral mucosa
Pink conj, anicteric sclera
Chest: crackles, left lung, no wheezing or stridor
left fingers: multiple ampulated

2025/12/23   HGB: 8.2 g/dl
2025/12/23   HCT: 24.4 %
2025/12/23   PLT: 298.0 10^3/ul
2025/12/23   W.B.C: 4.63 10^3/ul
2025/12/23   SEG: 63.3 %
2025/12/23   LYMPH: 25.9 %

2025/12/23   BUN: 14.8 mg/dL
2025/12/23   Creatinine: 0.95 mg/dL
2025/12/23   eGFR (MDRD): 83 mL/min/1.73^2
2025/12/23   Bilirubin Total: 0.37 mg/dL
2025/12/23   AST / GOT: 21 U/L
2025/12/23   ALT / GPT: 17 U/L
2025/12/23   Na: 128 mmol/L
2025/12/23   K: 4.0 mmol/L
2025/12/23   Ca: 8.8 mg/dL
2025/12/23   eGFR (CKD-EPI): 86.11 mL/min/1.73^2
評估與計畫
帶入到
S
O
A/P

1. Squamous cell carcinoma of the lung, LUL, collapse, 
- liver lesion, and vertebral lesion
s/p CCRT with vinorelbine/cisplatin x 4 cycles at CGMH in 2021
- 2023 recurrence
s/p oral vinorelbine
- 2025/03 progression
s/p gemcitabine/? cisplatin (2025/04~)

- 2025/04/23 first time to SYSCC, explained to patient, wife, and daughter about patient's disease status, likely advanced disease, agree to change oral vinorelbine to gemcitabine containing regimen. Life expectany is hard to make a guess.

s/p #4b gemcitabine/carboplatin (2025/05/07~8/18)

- 2025/06 CT scan: collapse of LUL, ever open (2025/05/07 CXR), DDx: sputum impaction vs. tumor obstruction? refer to chest doctor for evaluation and for management, biopsy: SqCC, continue chemotherapy, no RT because of prior exposure to the radiation,

- 2025/08 CT scan: progression
s/p #3b docetaxel (2025/09/02~11/18)

- 2025/12 CT scan: progression
- 2025/12 PD-L1 TPS = 10%

s/p VP-16 (2025/12/09~)

Blood type: A(+)

Plan:
@ 12/23 #2 VP-16, pRBC 2u stat
@ 2026/01/06 VP16, CXR
處方

